Insider Selling: Teladoc, Inc. (NYSE:TDOC) Insider Sells $1,663,681.52 in Stock

Teladoc, Inc. (NYSE:TDOC) insider Adam C. Vandervoort sold 53,806 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $30.92, for a total value of $1,663,681.52. Following the completion of the transaction, the insider now directly owns 33,008 shares in the company, valued at approximately $1,020,607.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Teladoc, Inc. (NYSE TDOC) opened at 30.35 on Friday. The stock has a 50 day moving average price of $33.88 and a 200 day moving average price of $27.52. The stock’s market capitalization is $1.72 billion. Teladoc, Inc. has a 12 month low of $14.00 and a 12 month high of $36.90.

Teladoc (NYSE:TDOC) last issued its earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.02. The company had revenue of $44.60 million during the quarter, compared to analyst estimates of $44.39 million. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The business’s revenue was up 68.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.38) earnings per share. On average, analysts anticipate that Teladoc, Inc. will post ($1.47) EPS for the current fiscal year.

A number of brokerages recently weighed in on TDOC. Zacks Investment Research raised Teladoc from a “sell” rating to a “hold” rating in a report on Thursday, May 11th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $42.00 price objective on shares of Teladoc in a report on Friday, July 28th. Chardan Capital upped their price objective on Teladoc from $30.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, June 20th. Craig Hallum lowered Teladoc from a “buy” rating to a “hold” rating and upped their price objective for the stock from $28.00 to $32.00 in a report on Friday, May 12th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $27.00 price objective on shares of Teladoc in a report on Monday, June 19th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $35.55.

Several hedge funds have recently modified their holdings of the company. Bank of Montreal Can boosted its stake in shares of Teladoc by 214.2% in the second quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after buying an additional 2,397 shares during the period. Pacad Investment Ltd. acquired a new stake in shares of Teladoc during the second quarter valued at approximately $135,000. Great West Life Assurance Co. Can acquired a new stake in shares of Teladoc during the first quarter valued at approximately $105,000. US Bancorp DE boosted its stake in shares of Teladoc by 10.3% in the first quarter. US Bancorp DE now owns 4,617 shares of the health services provider’s stock valued at $116,000 after buying an additional 433 shares during the period. Finally, Oppenheimer Asset Management Inc. acquired a new stake in shares of Teladoc during the second quarter valued at approximately $166,000. 95.88% of the stock is owned by institutional investors and hedge funds.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.